Clinical correlates of mdr1 (p-glycoprotein) gene expression in ovarian and small-cell lung carcinomas

Journal of the National Cancer Institute

Volumn 84, Issue 19, 1992, Pages 1486-1491

  Holzmayer, Tatyana A ^a   Hilsenbeck, Susan ^b   Von Hoff, Daniel D ^b   Roninson, Igor B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; MELPHALAN; MESSENGER RNA; MITOMYCIN C; THIOTEPA; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIPOPHILICITY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA ANALYSIS; SOLID TUMOR; TUMOR BIOPSY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RNA, MESSENGER; RNA, NEOPLASM; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026781491     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/84.19.1486     Document Type: Article

References (31)

1. Roninson IB, ed: Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York: Plenum Press, 1991
2. Pastan I, Gottesman MM: Multidrug resistance. Annu Rev Med 42:277–286, 1991
3. Endicott JA, Ljno V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137–171, 1989
4. Choi K, Frommel TO, Stern RK, et al: Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection. Proc Nat J Acad Sci U S A 88:7386–7390, 1991
5. Bell DR, Gerlach JH, Kartner N, et al: Detection of P-glycoprotein in ovarian cancer: A molecular marker associated with multidrug resistance. J Clin Oncol 3:311–315, 1985
6. Fojo AT, Ueda K, Slamon DJ, et al: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 84:265–269, 1987
7. Goldstein U, Galski H, Fojo A, et al: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116–124, 1989
8. Cordon-Cardo C, O’Brien JP, Boccia J, et al: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277–1287, 1990
9. Epstein J, Barlogie B: Tumor resistance to chemotherapy associated with expression of the multidrug resistance phenotype. Cancer Bull 41:41–44, 1989
10. Ro J, Sahin A, Ro JY, et al: Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21:787–791, 1990
11. Verrelle P, Meissonnier F, Fonck Y, et al: Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83:111–116, 1991
12. Robey-Cafferty SS, Rutledge ML, Bruner JM: Expression of a multidrug resistance gene in esophageal adenocarcinoma. Correlation with response to chemotherapy and comparison with gastric adenocarcinoma. Am J Clin Pathol 93:1–7, 1990
13. Sato H, Preisler H, Day R, et al: MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol 75:340–345, 1990
14. Pirker R, Wallner J, Geissler K: MDR1 gene expression and treatment outcome in acute rayeloid leukemia. J Natl Cancer Inst 83:708–712, 1991
15. Musto P, Meullo L, Lombardi G, et al High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 77:50–53, 1991
16. Chan HS, Thorner PS, Haddad G, et al: Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J C1in Oncol 8:689–704, 1990
17. Chan HS, Haddad G, Thorner PS, et al: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608–1614, 1991
18. Marie JP, Zittoun R, Sikic BI: Multidrug resistance (mdrl) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity. Blood 78:586–592, 1991
19. Sanfilippo O, Ronchi E, De Marco C, et al: Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristinc. Eur J Cancer 27:155–158, 1991
20. Salmon SE, Grooan TM, Miller T, et al: Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 81:696–701, 1989
21. Kanamaru H, Kakehi Y, Yoshida O, et al: MDR1 RNA levels in human renal cell carcinomas: Correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst 81:844–849, 1989
22. Noonan KE, Beck C, Holzmayer TA, et al Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A 87:7160–7164, 1990
23. Noonan KE, Roninson IB: Quantitative estimation of MDR1 raRNA levels by polymerase chain reaction. In Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells (Roninson IB, ed). New York: Plenum Press, 1991, pp 319–333
24. Young RC, Fuks Z, Hoskins WJ: Cancer of the ovary. In Cancer: Principles and Practice of Oncology (DeVita VT Jr, Hellman S, Rosenberg SA, eds). Philadelphia: Lippincott, 1989, pp 1162–1196
25. Conte PF, Bruzzone M, Chiara S, et al: A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer [published erratum appears in J Clin Oncol 8:1284, 1986]. J Clin Oncol 4:965–971, 1986
26. Conte PF, Bruzzone M, Chiara S, et al: A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer [published erratum appears in J Clin Oncol 8:1284, 1986]. J Clin Oncol 4:965–971, 1986
27. Thorgeirsson SS, Huber BE, Sorrell S, et al: Expression of the multidrug-resistance gene in hepatocarcinogenesis and regenerating rat liver. Science 236:1120–1122, 1987
28. Burt RK, Garfield S, Johnson K, et al: Transformation of rat liver epithelial cells with v-H-ras or v-raf causes expression of MDR-1, glutathione-5-transferase-P and increased resistance to cytotoxic chemicals. Carcinogenesis 9:2329–2332, 1988
29. Weinstein RS, Jakate SM, Dominguez JM, et al: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51:2720–2726, 1991
30. Hanania N, Boyano M-D, Manoin C, et al: Oncogene and MDR1 gene expression in rat rhabdomyosarcoma sublines of different meta-static potential. Anticancer Res 11:473–480, 1991
31. Roninson IB, Patel MC, Lee I, et al: Molecular mechanism and diagnostics of multidrug resistance in human tumor cells. In Cancer Cells (Furth M, Greaves M, eds), vol 7. New York: Cold Spring Harbor Laboratory, 1989, pp 81–86